AstraZeneca (AZN) Enters In-Lincensing Deal for Progenics' (PGNX) Clostridium Difficile Program
Go back to AstraZeneca (AZN) Enters In-Lincensing Deal for Progenics' (PGNX) Clostridium Difficile Program| ASTRAZENECA PLC (NASDAQ: AZN) | Delayed: 92.77 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $92.77 | 52 Week High | $35.04 | |||
| Open | $92.77 | 52 Week Low | $26.97 | |||
| Day High | $92.77 | P/E | N/A | |||
| Day Low | $92.77 | EPS | $0.00 | |||
| Volume | 9,567 | |||||
| Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) | Delayed: 4.10 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $4.10 | 52 Week High | $7.75 | |||
| Open | $111.64 | 52 Week Low | $3.61 | |||
| Day High | $4.10 | P/E | N/A | |||
| Day Low | $4.10 | EPS | $-0.62 | |||
| Volume | 6,812 | |||||
